Myelofibrosis epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(→Gender) |
||
| (17 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}}{{AE}}{{SR}} | {{CMG}}{{Sab}}{{AE}}{{SR}} | ||
==Overview== | ==Overview== | ||
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population | The [[prevalence]] of [[myelofibrosis]] is approximately 1 per 100,000 individuals worldwide. [[Myelofibrosis]] is a [[disease]] that tends to affect the middle-aged and elderly population with a [[mean]] age of 60 years at [[diagnosis]]. [[Male|Males]] are more commonly affected than [[Female|females]]. The [[male]] to [[female]] ratio is approximately 1.5 to 1. [[Myelofibrosis]] usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop [[myelofibrosis]]. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | |||
*In the countries of the European Union, the [[incidence]] of [[myelofibrosis]] ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average [[incidence]] of 1.1 per 100,000 persons.<ref name="pmid24372927" /> | |||
*In Olmstead County, Minnesota USA, the annual [[incidence]] of [[Primary myelofibrosis|primary myelofibrosis (PMF)]] has been reported to be 1.33 per 100,000.<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref> | |||
===Prevalence=== | ===Prevalence=== | ||
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.<ref name= | *The [[prevalence]] of [[myelofibrosis]] is approximately 1 per 100,000 individuals worldwide. | ||
*In developed countries, the [[prevalence]] of [[myelofibrosis]] is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.<ref name="pmid24372927">{{cite journal |vauthors=Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA |title=Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union |journal=Eur. J. Haematol. |volume=92 |issue=4 |pages=289–97 |date=April 2014 |pmid=24372927 |doi=10.1111/ejh.12256 |url=}}</ref> | |||
===Case-fatality rate/Mortality rate=== | |||
* In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%. | |||
* The case-fatality rate/mortality rate of [disease name] is approximately [number range]. | |||
===Age=== | ===Age=== | ||
Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.<ref name= | [[Myelofibrosis]] is a [[disease]] that tends to affect the middle-aged and elderly population. The [[mean]] age at [[diagnosis]] is 60 years.<ref name="pmid17312082">{{cite journal |vauthors=Cloran F, Banks KP |title=AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly |journal=AJR Am J Roentgenol |volume=188 |issue=3 Suppl |pages=S18–20 |date=March 2007 |pmid=17312082 |doi=10.2214/AJR.05.2141 |url=}}</ref><ref name="pmid9488952">{{cite journal |vauthors=Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E |title=[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients] |language=Spanish; Castilian |journal=Med Clin (Barc) |volume=109 |issue=17 |pages=651–5 |date=November 1997 |pmid=9488952 |doi= |url=}}</ref> | ||
===Race=== | |||
*[[Myelofibrosis]] is more [[Prevalence|prevalent]] in the Ashkenazi Jews with an evidence of [[genetic]] [[Transmission (genetics)|transmission]].<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref> | |||
===Gender=== | ===Gender=== | ||
Males are more commonly affected with myelofibrosis than females | *Gender distribution can differ by the subtype of the [[disease]] with [[Primary myelofibrosis|primary myelofibrosis (PMF)]] being more [[Prevalence|prevalent]] in [[Male|males]] and post-[[essential thrombocythemia]] being more common in [[Female|females]].<ref name="pmid27540137">{{cite journal |vauthors=Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA |title=Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group |journal=Haematologica |volume=102 |issue=1 |pages=85–93 |date=January 2017 |pmid=27540137 |pmc=5210236 |doi=10.3324/haematol.2016.149559 |url=}}</ref> | ||
*[[Male|Males]] are more commonly affected with [[myelofibrosis]] than [[Female|females]] with a [[male]] to [[female]] ratio of approximately 1.5 to 1.<ref name="pmid22212965">{{cite journal| author=Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R et al.| title=One thousand patients with primary myelofibrosis: the mayo clinic experience. | journal=Mayo Clin Proc | year= 2012 | volume= 87 | issue= 1 | pages= 25-33 | pmid=22212965 | doi=10.1016/j.mayocp.2011.11.001 | pmc=PMC3538387 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22212965 }} </ref> | |||
==References== | ==References== | ||
| Line 26: | Line 37: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Latest revision as of 15:20, 12 November 2019
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis epidemiology and demographics |
|
Risk calculators and risk factors for Myelofibrosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Sabawoon Mirwais, M.B.B.S, M.D.[2]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [3]
Overview
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide. Myelofibrosis is a disease that tends to affect the middle-aged and elderly population with a mean age of 60 years at diagnosis. Males are more commonly affected than females. The male to female ratio is approximately 1.5 to 1. Myelofibrosis usually affects individuals of the Ashkenazi Jews race. African American, Latin American, and Asian individuals are less likely to develop myelofibrosis.
Epidemiology and Demographics
Incidence
- In the countries of the European Union, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons with an average incidence of 1.1 per 100,000 persons.[1]
- In Olmstead County, Minnesota USA, the annual incidence of primary myelofibrosis (PMF) has been reported to be 1.33 per 100,000.[2]
Prevalence
- The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.
- In developed countries, the prevalence of myelofibrosis is ranged from 0.5 per 100,000 per year to 9 per 100,000 per year.[1]
Case-fatality rate/Mortality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
- The case-fatality rate/mortality rate of [disease name] is approximately [number range].
Age
Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.[3][4]
Race
- Myelofibrosis is more prevalent in the Ashkenazi Jews with an evidence of genetic transmission.[5]
Gender
- Gender distribution can differ by the subtype of the disease with primary myelofibrosis (PMF) being more prevalent in males and post-essential thrombocythemia being more common in females.[6]
- Males are more commonly affected with myelofibrosis than females with a male to female ratio of approximately 1.5 to 1.[7]
References
- ↑ 1.0 1.1 Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (April 2014). "Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union". Eur. J. Haematol. 92 (4): 289–97. doi:10.1111/ejh.12256. PMID 24372927.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Cloran F, Banks KP (March 2007). "AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly". AJR Am J Roentgenol. 188 (3 Suppl): S18–20. doi:10.2214/AJR.05.2141. PMID 17312082.
- ↑ Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E (November 1997). "[Idiopathic myelofibrosis: initial features, evolutive patterns and survival in a series of 106 patients]". Med Clin (Barc) (in Spanish; Castilian). 109 (17): 651–5. PMID 9488952.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.
- ↑ Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA (January 2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.
- ↑ Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R; et al. (2012). "One thousand patients with primary myelofibrosis: the mayo clinic experience". Mayo Clin Proc. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. PMC 3538387. PMID 22212965.